{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:08:49Z","timestamp":1747224529003,"version":"3.40.5"},"reference-count":24,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Monaldi Arch Chest Dis"],"abstract":"<jats:p>To the Editor\nCOVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors...<\/jats:p>","DOI":"10.4081\/monaldi.2021.1721","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:30:39Z","timestamp":1620189039000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target"],"prefix":"10.4081","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-1235","authenticated-orcid":false,"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0160-3674","authenticated-orcid":false,"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"4348","doi-asserted-by":"crossref","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.","DOI":"10.1001\/jama.2020.2648"},{"key":"4349","doi-asserted-by":"crossref","unstructured":"Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417\u00e2\u20ac\u201c35.","DOI":"10.1016\/j.antiviral.2013.06.018"},{"key":"4350","doi-asserted-by":"crossref","unstructured":"Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.","DOI":"10.1378\/chest.06-1997"},{"key":"4351","doi-asserted-by":"crossref","unstructured":"Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642.","DOI":"10.1136\/bmj.d1642"},{"key":"4352","doi-asserted-by":"crossref","unstructured":"Shrivastava-Ranjan P, Flint M, Bergeron \u00c3\u2030, et al. Statins suppress Ebola virus infectivity by interfering with glycoprotein processing. mBio 2018;9:e00660-18.","DOI":"10.1128\/mBio.00660-18"},{"key":"4353","doi-asserted-by":"crossref","unstructured":"Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio 2015;6:e01120.","DOI":"10.1128\/mBio.01120-15"},{"key":"4354","doi-asserted-by":"crossref","unstructured":"Gupta A, Madhavan M V, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Res Sq 2020; rs.3.rs-56210. Preprint","DOI":"10.21203\/rs.3.rs-56210\/v1"},{"key":"4355","doi-asserted-by":"crossref","unstructured":"Fan Y, Guo T, Yan F, et al. Association of statin use with the in-hospital outcomes of 2019-coronavirus disease patients: A retrospective study. Front Med (Lausanne) 2020;7:584870.","DOI":"10.3389\/fmed.2020.584870"},{"key":"4356","doi-asserted-by":"crossref","unstructured":"Zhang X-J, Qin J-J, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 2020;32:176-87.e4.","DOI":"10.1016\/j.cmet.2020.06.015"},{"key":"4357","doi-asserted-by":"crossref","unstructured":"Saeed O, Castagna F, Agalliu I, et al. Statin use and in\u00e2\u20ac\u0090hospital mortality in diabetics with COVID\u00e2\u20ac\u009019. J Am Heart Assoc 2020;9:e018475.","DOI":"10.1161\/JAHA.120.018475"},{"key":"4358","doi-asserted-by":"crossref","unstructured":"Song SL, Hays SB, Panton CE, et al. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: A preliminary study. Pathogens 2020;9:759.","DOI":"10.3390\/pathogens9090759"},{"key":"4359","doi-asserted-by":"crossref","unstructured":"Daniels LB, Sitapati AM, Zhang J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol 2020;136:149-55.","DOI":"10.1016\/j.amjcard.2020.09.012"},{"key":"4360","doi-asserted-by":"crossref","unstructured":"Butt JH, Gerds TA, Schou M, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open 2020;10:e044421.","DOI":"10.1136\/bmjopen-2020-044421"},{"key":"4361","doi-asserted-by":"crossref","unstructured":"Cariou B, Goronflot T, Rimbert A, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab 202;101202.","DOI":"10.1016\/j.diabet.2020.10.001"},{"key":"4362","doi-asserted-by":"crossref","unstructured":"Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol 2020;134:153\u00e2\u20ac\u201c5.","DOI":"10.1016\/j.amjcard.2020.08.004"},{"key":"4363","doi-asserted-by":"crossref","unstructured":"Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 2020;14:1613\u00e2\u20ac\u201c5.","DOI":"10.1016\/j.dsx.2020.08.023"},{"key":"4364","doi-asserted-by":"crossref","unstructured":"Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab 2020;47:101220.","DOI":"10.1016\/j.diabet.2020.101220"},{"key":"4365","doi-asserted-by":"crossref","unstructured":"Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION\/INSPIRATION-S studies. Thromb Res 2020;196:382\u00e2\u20ac\u201c94.","DOI":"10.1016\/j.thromres.2020.09.027"},{"key":"4366","doi-asserted-by":"crossref","unstructured":"Cesaro A, Bianconi V, Gragnano F, et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long\u00e2\u20ac\u0090term inhibition. Biofactors 2020;46:367-80.","DOI":"10.1002\/biof.1619"},{"key":"4367","doi-asserted-by":"crossref","unstructured":"Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis 2020;313:126-36.","DOI":"10.1016\/j.atherosclerosis.2020.09.008"},{"key":"4368","doi-asserted-by":"crossref","unstructured":"Mureddu GF, Ambrosetti M, Venturini E, et al. Cardiac rehabilitation activities during the COVID-19 pandemic in Italy. Position Paper of the AICPR (Italian Association of Clinical Cardiology, Prevention and Rehabilitation). Monaldi Arch Chest Dis 2020;90:1439.","DOI":"10.4081\/monaldi.2020.1439"},{"key":"4369","doi-asserted-by":"crossref","unstructured":"Gragnano F, Natale F, Concilio C, et al. Adherence to proprotein convertase subtilisin\/kexin 9 inhibitors in high cardiovascular risk patients: An Italian single-center experience. J Cardiovasc Med 2018;19:75\u00e2\u20ac\u201c7.","DOI":"10.2459\/JCM.0000000000000611"},{"key":"4370","doi-asserted-by":"crossref","unstructured":"Cesaro A, Gragnano F, Fimiani F, et al. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. Eur J Prev Cardiol 2020;27:556-8.","DOI":"10.1177\/2047487319839179"},{"key":"4371","doi-asserted-by":"crossref","unstructured":"Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019;26:824-35.","DOI":"10.1177\/2047487318825350"}],"container-title":["Monaldi Archives for Chest Disease"],"original-title":[],"link":[{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/download\/1721\/1195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/download\/1721\/1195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:31:19Z","timestamp":1620189079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.monaldi-archives.org\/index.php\/macd\/article\/view\/1721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,5]]}},"URL":"https:\/\/doi.org\/10.4081\/monaldi.2021.1721","relation":{},"ISSN":["2532-5264","1122-0643"],"issn-type":[{"type":"electronic","value":"2532-5264"},{"type":"print","value":"1122-0643"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}